Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report released on Saturday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 4.0 %

Lipocine stock opened at $3.68 on Friday. Lipocine has a 12 month low of $2.91 and a 12 month high of $11.79. The company has a market capitalization of $19.69 million, a price-to-earnings ratio of -4.84 and a beta of 1.42. The business’s fifty day simple moving average is $3.77 and its two-hundred day simple moving average is $4.53.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.